BILASTINE TEVA 20 mg, tablet 30 tablets, CIP 3400930227992
Active ingredients: Bilastine
Commercialized according to BDPMDispensing in France: Prescription only
Tablet30 tablets, CIP 3400930227992orale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- BILASTINE TEVA 20 mg, comprimé
- Pharmaceutical form
- comprimé
- Route of administration
- orale
- Presentation description
- plaquette(s) OPA : polyamide orienté aluminium PVC-Aluminium de 30 comprimé(s)
- Marketing authorisation holder
- TEVA (PAYS-BAS)
- Reimbursement according to BDPM
- 30 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 3 Jun 2022
- Prescription and dispensing conditions
- Prescription only
- List II: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
61629890CIP73022799CIP133400930227992Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| BILASTINEcomprimé | 20 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.